High frequency of congenital thrombophilia in women with pathological pregnancies?

Ase Rasmussen, Pernille Ravn

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2004-Sep
OriginalsprogEngelsk
TidsskriftActa Obstetricia et Gynecologica Scandinavica
Vol/bind83
Udgave nummer9
Sider (fra-til)808-17
Antal sider9
ISSN0001-6349
DOI
StatusUdgivet - 1. sep. 2004

Fingeraftryk

Thrombophilia
Abruptio Placentae
Pre-Eclampsia
Growth
Placental Insufficiency
Mothers
Clinical Trials
Guidelines
Research

Citer dette

@article{b7a849306c6c11ddb1a1000ea68e967b,
title = "High frequency of congenital thrombophilia in women with pathological pregnancies?",
abstract = "The obstetrical complications preeclampsia, intrauterine growth restriction (IUGR), placental abruption and fetal loss are major causes of maternal and fetal morbidity and mortality. Much recent research has focused on to what extent congenital thrombophilia contributes to these obstetrical complications. Combined with the hypercoagulable state of pregnancy, thrombophilia has the potential to induce placental thrombosis and cause placental insufficiency with subsequent obstetrical complications. This article aims to review and discuss published clinical studies of the relationship between congenital thrombophilia and preeclampsia, IUGR, placental abruption and fetal loss. In addition, the few published clinical trials of prophylactic antithrombotic treatment to prevent severe obstetrical complications in thrombophilic women are discussed. The studies have shown variable results evaluated mainly as a result of the limited number of case reports published. However, the strongest association was found to be between congenital thrombophilia and preeclampsia and late fetal loss. Early fetal loss was not found to be associated with congenital thrombophilia. At present, the question remains open as to whether IUGR and placental abruption is directly associated with thrombophilia or mediated through preeclampsia. In conclusion, the associations between congenital thrombophilia and preeclampsia, IUGR, placental abruption and fetal loss only reaches evidence grade 4. Present recommendations and clinical guidelines are thus based on weak scientific proof.",
keywords = "Adult, Comorbidity, Female, Fetal Death, Fetal Growth Retardation, Follow-Up Studies, Gestational Age, Humans, Incidence, Infant Mortality, Infant, Newborn, Maternal Mortality, Obstetric Labor Complications, Pre-Eclampsia, Pregnancy, Pregnancy Complications, Hematologic, Pregnancy Outcome, Risk Assessment, Severity of Illness Index, Thrombophilia",
author = "Ase Rasmussen and Pernille Ravn",
year = "2004",
month = "9",
day = "1",
doi = "10.1111/j.0001-6349.2004.00566.x",
language = "English",
volume = "83",
pages = "808--17",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "JohnWiley & Sons Ltd.",
number = "9",

}

High frequency of congenital thrombophilia in women with pathological pregnancies? / Rasmussen, Ase; Ravn, Pernille.

I: Acta Obstetricia et Gynecologica Scandinavica, Bind 83, Nr. 9, 01.09.2004, s. 808-17.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - High frequency of congenital thrombophilia in women with pathological pregnancies?

AU - Rasmussen, Ase

AU - Ravn, Pernille

PY - 2004/9/1

Y1 - 2004/9/1

N2 - The obstetrical complications preeclampsia, intrauterine growth restriction (IUGR), placental abruption and fetal loss are major causes of maternal and fetal morbidity and mortality. Much recent research has focused on to what extent congenital thrombophilia contributes to these obstetrical complications. Combined with the hypercoagulable state of pregnancy, thrombophilia has the potential to induce placental thrombosis and cause placental insufficiency with subsequent obstetrical complications. This article aims to review and discuss published clinical studies of the relationship between congenital thrombophilia and preeclampsia, IUGR, placental abruption and fetal loss. In addition, the few published clinical trials of prophylactic antithrombotic treatment to prevent severe obstetrical complications in thrombophilic women are discussed. The studies have shown variable results evaluated mainly as a result of the limited number of case reports published. However, the strongest association was found to be between congenital thrombophilia and preeclampsia and late fetal loss. Early fetal loss was not found to be associated with congenital thrombophilia. At present, the question remains open as to whether IUGR and placental abruption is directly associated with thrombophilia or mediated through preeclampsia. In conclusion, the associations between congenital thrombophilia and preeclampsia, IUGR, placental abruption and fetal loss only reaches evidence grade 4. Present recommendations and clinical guidelines are thus based on weak scientific proof.

AB - The obstetrical complications preeclampsia, intrauterine growth restriction (IUGR), placental abruption and fetal loss are major causes of maternal and fetal morbidity and mortality. Much recent research has focused on to what extent congenital thrombophilia contributes to these obstetrical complications. Combined with the hypercoagulable state of pregnancy, thrombophilia has the potential to induce placental thrombosis and cause placental insufficiency with subsequent obstetrical complications. This article aims to review and discuss published clinical studies of the relationship between congenital thrombophilia and preeclampsia, IUGR, placental abruption and fetal loss. In addition, the few published clinical trials of prophylactic antithrombotic treatment to prevent severe obstetrical complications in thrombophilic women are discussed. The studies have shown variable results evaluated mainly as a result of the limited number of case reports published. However, the strongest association was found to be between congenital thrombophilia and preeclampsia and late fetal loss. Early fetal loss was not found to be associated with congenital thrombophilia. At present, the question remains open as to whether IUGR and placental abruption is directly associated with thrombophilia or mediated through preeclampsia. In conclusion, the associations between congenital thrombophilia and preeclampsia, IUGR, placental abruption and fetal loss only reaches evidence grade 4. Present recommendations and clinical guidelines are thus based on weak scientific proof.

KW - Adult

KW - Comorbidity

KW - Female

KW - Fetal Death

KW - Fetal Growth Retardation

KW - Follow-Up Studies

KW - Gestational Age

KW - Humans

KW - Incidence

KW - Infant Mortality

KW - Infant, Newborn

KW - Maternal Mortality

KW - Obstetric Labor Complications

KW - Pre-Eclampsia

KW - Pregnancy

KW - Pregnancy Complications, Hematologic

KW - Pregnancy Outcome

KW - Risk Assessment

KW - Severity of Illness Index

KW - Thrombophilia

U2 - 10.1111/j.0001-6349.2004.00566.x

DO - 10.1111/j.0001-6349.2004.00566.x

M3 - Journal article

VL - 83

SP - 808

EP - 817

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 9

ER -